Acumen Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Acumen Pharmaceuticals, a clinical stage biopharmaceutical company focused on Alzheimer's disease, announced participation in two upcoming virtual conferences. The first is the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, at 9:40 AM EST, followed by the Stifel 2021 Healthcare Conference on November 16, 2021, at 10:00 AM EST. Live webcasts will be accessible on-demand for 30 days after each event on their website. Acumen is advancing its investigational product ACU193, targeting toxic AβOs in early Alzheimer's patients.

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming virtual conferences:

• Credit Suisse 30^th Annual Healthcare Conference on Tuesday, November 9, 2021, at 9:40 AM EST
• Stifel 2021 Healthcare Conference on Tuesday, November 16, 2021, at 10:00 AM EST

Live audio webcasts will be available for on-demand viewing and will be available on the Investors section of the company’s website at www.acumenpharm.com. Replays will be available after the events and archived on the Investors section of the company’s website at www.acumenpharm.com for 30 days.

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, headquartered in Charlottesville, Va. with clinical operations based in Carmel, Ind., is a clinical stage biopharmaceutical company developing a novel disease-modifying approach to treat Alzheimer’s disease. Acumen’s scientific founders pioneered research on toxic soluble AβOs, which a growing body of evidence indicates are primary triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, ACU193, a humanized monoclonal antibody that selectively targets toxic soluble AOs in a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Contacts:

Media:
AcumenPR@westwicke.com

Investors:
investors@acumenpharm.com 

 

FAQ

What conferences will Acumen Pharmaceuticals participate in November 2021?

Acumen Pharmaceuticals will participate in the Credit Suisse 30th Annual Healthcare Conference on November 9, 2021, and the Stifel 2021 Healthcare Conference on November 16, 2021.

What is the focus of Acumen Pharmaceuticals?

Acumen Pharmaceuticals focuses on developing novel therapeutics for Alzheimer's disease.

What is ACU193?

ACU193 is Acumen's investigational humanized monoclonal antibody targeting toxic soluble AβOs in early Alzheimer's disease patients.

Where can I watch the conferences featuring Acumen Pharmaceuticals?

The conferences can be watched via live webcasts available on Acumen Pharmaceuticals' website.

How long will the conference replays be available?

The replays of the conferences will be available for 30 days after the events.